Serum lipids in postmenopausal or perimenopausal women using estrogen alone, estrogen with levonorgestrel, or estrogen with norethisterone, compared with nonusers: Results from a crosssectional study in two Norwegian counties 1985-1988

Journal of Clinical Epidemiology

Volumn 51, Issue 12, 1998, Pages 1311-1316

  Graff Iversen, Sidsel ^a   Stensvold, Inger ^a   Lund Larsen, Per G ^a   Nodarse, Leandro Orozco ^a   Tverdal, Aage ^a   Urdal, Petter ^b  

^a National Health Screening Services   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

BMI; Estrogen; HDL cholesterol; Hormone replacement therapy; Menopause; Progestin

Indexed keywords

ESTROGEN; LEVONORGESTREL; NORETHISTERONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MENOPAUSE; NORMAL HUMAN; NORWAY; PRIORITY JOURNAL;

EID: 0032441828     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(98)00123-1     Document Type: Article

References (47)

1. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease. A quantitative assessment of the epidemiologic evidence Prev Med. 20:1991;47-63.
2. Grady D., Rubin S.M., Pettiti D.B., Fox C.S., Black D., Ettinger B.et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
3. Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M.et al. Cardiovascular mortality and noncontraceptive use of estrogen in women. Results from the Lipid Research Clinics Program Follow-up Study Circulation. 75:1987;1102-1109.
4. Grodstein F., Stampfer M.J., Manson J.A., Colditz G.A., Willett W.C., Rosner B.et al. Postmenopausal estrogen and progestin use and risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
5. Hernandez A.M., Walker A.M., Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1:1990;128-133.
6. Rosenberg L., Palmer J.R.P., Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 137:1993;54-63.
7. Hemminiki E., McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Pooled data from clinical trials BMJ. 315:1997;149-153.
8. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.A., Joffe M.et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
9. Egeland G.M., Kuller L.H., Mattews K.A., Kelsey S.F., Cauley J., Guzick D. Premenopausal determinants of menopausal estrogen use. Prev Med. 20:1991;343-349.
10. Derby C.A., Hume A.L., Barbour M.M., McPhillips J.B., Lasater T.M., Carleton R.A. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol. 137:1993;1125-1135.
11. Hemminki E., Malin M., Topo P. Selection of postmenopausal therapy by women's characteristics. J Clin Epidemiol. 46:1993;211-219.
12. Johannes C.B., Crawford S.L., Posner J.G., McKinlay S.M. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol. 140:1994;439-452.
13. Mattews K.A., Kuller L.H., Wing R.B., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than non-users? Am J Epidemiol. 143:1996;971-978.
14. Colditz G.A., Stampfer M.J., Willett W.C., Hennechens C.H., Rosner B., Speizer F.E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 264:1990;2648-2653.
15. Sturgeon S.R., Schairer C., Brinton L.A., Pearson T., Hoover R.N. Evidence of a healthy estrogen user survivor effect. Epidemiology. 6:1995;227-231.
16. Posthuma W.F.M., Westendorp R.G.J., Vandenbroucke J.P. Cardioprotective effect of hormone replacement therapy in postmenopausal women. Is the evidence biased? BMJ. 308:1994;1268-1269.
17. Hjortland M.C., McNamara P.M., Kannel W.B. Some atherogenic concomitants of menopause. The Framingham study Am J Epidemiol. 103:1976;304-311.
18. Beresteijn E.C.H., Korevaar J.C.W., Huijbregts P.C., Schouten E.G., Burema J., Kok F.J. Perimenopausal increase in serum cholesterol. A 10-year longitudinal study Am J Epidemiol. 137:1993;383-392.
19. Mattews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med. 321:1989;641-646.
20. Stevenson J.C., Crook D., Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 98:1993;83-90.
21. Seed M. Sex hormones, lipoproteins, and cardiovascular risk. Atherosclerosis. 90:1991;1-7.
22. Darling G.M., Johns J.A., McCloud P.I., Davis S. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 337:1997;595-601.
23. Walch B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1991;1196-1204.
24. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K.et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 328:1993;1069-1075.
25. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
26. Tikkanen M.J., Nikkilä E.A., Kuusi T., Sipinen S. Different effects of two progestins on plasma high density lipoprotein (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis. 40:1981;365-369.
27. Ottosson U.B., Johansson B.G., von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy. A comparison between progestogens and natural progesterone J Obstet Gynecol. 151:1985;746-750.
28. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. JAMA. 265:1991;1861-1867.
29. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
30. Midgette A.S., Baron J.A. Cigarette smoking and the risk of natural menopause. Epidemiology. 1:1990;474-480.
31. Willett W.C., Henneckens C.H., Castelli W., Rosner B., Evans D., Taylor J.et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol and high density lipoprotein cholesterol in women. Am Heart J. 105:1983;417-421.
32. Bjartveit K., Foss P.O., Gjervig T., Lund-Larsen P.G. The cardiovascular disease study in Norwegian counties. Background and organization. ACTA Med Scand. Suppl 634:1985;1-70.
33. Röschlau P., Bernt E., Gruber W. Enzymatische Bestimmung des Gesamt-cholesterin in Serum. Z Klin Chem Biochem. 12:1974;403-407.
34. Eggstein M., Kreutz F.H. Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. Klin Wochenschr. 44:1966;262-267.
35. Burstein M., Scholinik H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum precipitation by polyanions. J Lipid Res. 11:1970;583-595.
36. Stensvold I., Tverdal A., Urdal P., Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle-aged Norwegian women. BMJ. 307:1993;1318-1322.
37. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultrasentrifuge. Clin Chem. 18:1972;499-502.
38. Norusis MJ/SPSS Inc. SPSS Base System Users Guide. Chicago: SPSS Inc.; 1990.
39. Tikkanen M.J., Nikkilä E.A., Kuusi T., Sipinen S. High density lipoprotein-2 and hepatic lipase. reciprocal changes produced by estrogen and norgestrel J Clin Endocrinol Metab. 54:1982;1113-1117.
40. Gaziano J.M., Buring J.E., Breslow J.L., Goldhaber S.Z., Rosner B., VanDenburg M. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 329:1993;1829-1834.
41. Haertel U., Heiss G., Filipiak B., Doering A. Cross-sectional and longitudinal associations between high density lipoprotein cholesterol and women's employment. Am J Epidemiol. 135:1992;68-78.
42. Icovics J.R., Morrill A.C., Meisler A.W., Rodin J., Bromberger J.T., Mattews K.A. Employment and coronary risk in women at midlife. A longitudinal analysis Am J Epidemiol. 143:1996;144-150.
43. Jensen J., Nilas L., Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynaecol. 93:1986;613-618.
44. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 84:1994;987-995.
45. Barrett-Connor E., Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 10:1990;531-534.
46. Gambacciani M., Ciaponi M., Cappagli B., Piaggesi L., De Simone L., Orlandi R.et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 82:1997;414-417.
47. Graff-Iversen S., Tverdal A. Serum lipids in women aged 40-42 by use of different female sex hormone regimens [abstract no. 0966]. Can J Cardiol. 13(suppl B):1997;273B.